Literature DB >> 19665949

Analysis of endogenous ATP analogs and mevalonate pathway metabolites in cancer cell cultures using liquid chromatography-electrospray ionization mass spectrometry.

Marjo Jauhiainen1, Hannu Mönkkönen, Johanna Räikkönen, Jukka Mönkkönen, Seppo Auriola.   

Abstract

Nitrogen-containing bisphosphonates (N-BPs) are shown to inhibit a key enzyme of intracellular mevalonate pathway, FPP synthase, leading to intracellular accumulation of pathway metabolites isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP). In our previous studies we have shown that a new type of ATP analog, ApppI (triphosphoric acid 1-adenosin-5'-yl ester 3-(3-methylbut-3-enyl) ester), is also formed in addition to IPP and DMAPP accumulation. ApppI has cytotoxic effects leading to direct apoptosis of various cancer cells. In this study we present a validated method based on ion-pair LC-MS(2) for the analysis of isomeric mevalonate pathway metabolites and ATP analogs in cell culture samples. Limit of quantitation for IPP and DMAPP was 0.030microM (1.35fmol on-column) and for ApppI and ApppD 0.020microM (0.9fmol on-column). Acceptable accuracies and precision were also obtained for quality control samples in low and high concentrations of the calibration curve. In addition, we present a new method for quantitation of each coeluting isomer utilizing the peak intensity ratios of two characteristic fragment ions of each compound. For IPP and DMAPP, fragment ions m/z 177 and m/z 159 in the MS(2) were monitored, whereas for ATP analogs, ApppI and ApppD (triphosphoric acid 1-adenosin-5'-yl ester 3-(3-methylbut-2-enyl) ester), the same fragments in the MS(3) spectra were followed. IPP and DMAPP accumulation as well as ApppI and ApppD formation was demonstrated using MCF-7 breast cancer cells. Cells were treated with 25muM zoledronic acid (an N-BP) for 24h, conditions found to induce significant production of the metabolites. We found that the total amount of IPP and DMAPP was 2.4nmol/mg of protein and amount of ApppI and ApppD was 1.1nmol/mg protein. Relative portions of the isomers were approximately 1:4 IPP:DMAPP and 3:7 ApppI:ApppD. Untreated control samples did not contain IPP, DMAPP, ApppI or ApppD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19665949     DOI: 10.1016/j.jchromb.2009.07.010

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  15 in total

1.  Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity.

Authors:  Maria Raffaella Zocchi; Delfina Costa; Roberta Venè; Francesca Tosetti; Nicoletta Ferrari; Simona Minghelli; Roberto Benelli; Stefano Scabini; Emanuele Romairone; Silvia Catellani; Aldo Profumo; Alessandro Poggi
Journal:  Oncoimmunology       Date:  2017-01-06       Impact factor: 8.110

2.  Indirect stimulation of human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism.

Authors:  Hong Wang; Ghanashyam Sarikonda; Kia-Joo Puan; Yoshimasa Tanaka; Ju Feng; José-Luis Giner; Rong Cao; Jukka Mönkkönen; Eric Oldfield; Craig T Morita
Journal:  J Immunol       Date:  2011-10-19       Impact factor: 5.422

3.  Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vγ2Vδ2 T cells.

Authors:  Hong Wang; Olivier Henry; Mark D Distefano; Yen-Chih Wang; Johanna Räikkönen; Jukka Mönkkönen; Yoshimasa Tanaka; Craig T Morita
Journal:  J Immunol       Date:  2013-07-05       Impact factor: 5.422

4.  Rapid reverse phase-HPLC assay of HMG-CoA reductase activity.

Authors:  Matteo Mozzicafreddo; Massimiliano Cuccioloni; Anna Maria Eleuteri; Mauro Angeletti
Journal:  J Lipid Res       Date:  2010-04-24       Impact factor: 5.922

5.  Quantitative determination of geranyl diphosphate levels in cultured human cells.

Authors:  Sarah A Holstein; Huaxiang Tong; Craig H Kuder; Raymond J Hohl
Journal:  Lipids       Date:  2009-10-24       Impact factor: 1.880

6.  ATP synthase ecto-α-subunit: a novel therapeutic target for breast cancer.

Authors:  Jian Pan; Li-Chao Sun; Yan-Fang Tao; Zhuan Zhou; Xiao-Li Du; Liang Peng; Xing Feng; Jian Wang; Yi-Ping Li; Ling Liu; Shui-Yan Wu; Yan-Lan Zhang; Shao-Yan Hu; Wen-Li Zhao; Xue-Ming Zhu; Guo-Liang Lou; Jian Ni
Journal:  J Transl Med       Date:  2011-12-08       Impact factor: 5.531

7.  Phosphoantigen Burst upon Plasmodium falciparum Schizont Rupture Can Distantly Activate Vγ9Vδ2 T Cells.

Authors:  Marianne Guenot; Séverine Loizon; Jennifer Howard; Giulia Costa; David A Baker; Shaneel Y Mohabeer; Marita Troye-Blomberg; Jean-François Moreau; Julie Déchanet-Merville; Odile Mercereau-Puijalon; Maria Mamani-Matsuda; Charlotte Behr
Journal:  Infect Immun       Date:  2015-07-13       Impact factor: 3.441

8.  Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo.

Authors:  Jouko Sandholm; Jaakko Lehtimäki; Tamiko Ishizu; Sadanandan E Velu; Jeremy Clark; Pirkko Härkönen; Arja Jukkola-Vuorinen; Aleksi Schrey; Kevin W Harris; Johanna M Tuomela; Katri S Selander
Journal:  Oncotarget       Date:  2016-12-27

9.  Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer.

Authors:  Sophie Tardoski; Jacqueline Ngo; Evelyne Gineyts; Jean-Paul Roux; Philippe Clézardin; David Melodelima
Journal:  Sci Rep       Date:  2015-11-18       Impact factor: 4.379

Review 10.  Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer.

Authors:  Timm Hoeres; Manfred Smetak; Dominik Pretscher; Martin Wilhelm
Journal:  Front Immunol       Date:  2018-04-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.